Aclerastide, also known as DSC-127; NorLeu-3-A (1-7); NorLeu-3A (1-7), is an angiotensin receptor agonist potentially for the treatment of tissue regeneration in diabetic ulcers. Administration of NorLeu3-A (1-7) reduced fibrosis and scarring in the healing wounds. This action was more pronounced with longer administration of the peptide after injury. The action of this peptide was blocked by the AT receptor antagonist d-Ala7-angiotensin (1-7), which suggests that this receptor is involved in the healing responses to exogenous NorLeu3-A (1-7). Aclerastide may have the potential in accelerating wound repair and reducing scar formation. Aclerastide has been investigated for the treatment of Diabetic Foot, Diabetic Foot Ulcers, and Foot Ulcer, Diabetic.  >> Read More

1. High fat diet and GLP-1 drugs induce pancreatic injury in mice

2. Myotropic activity of allatostatins in tenebrionid beetles

3. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

4. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats

5. Olfactory receptor based piezoelectric biosensors for detection of alcohols related to food safety applications

Preclinical and clinical research shows that DSC127 is highly effective in the closure of diabetic wounds and is superior to Regranex in animal studies. Clinical development of DSC127 as a topical agent for the healing of DFU is underway. Further investigation into the mechanisms by which this product accelerates healing is warranted.

NorLeu3-Angiotensin (1-7) [DSC127] as a Therapy for the Healing of Diabetic Foot Ulcers

Derma Sciences, a tissue regeneration company focused on advanced wound and burn care, announced the termination of its Phase III clinical trials with aclerastide (DSC 127) for diabetic foot ulcer healing. This action is based on futility determinations conducted by the Data Monitoring Committee (DMC) for the planned, pre-specified interim analyses regarding the primary efficacy endpoint of confirmed complete wound closure of the target ulcer within 12 weeks of the start of treatment.

DSC 127 (aclerastide) fails diabetic foot ulcer healing trial and programme is cancelled- Derma Sciences Inc.